Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.
Individuals aged 2 months (minimum 6 weeks), 7 months to 5 years, and 18 years a... [+9]
Preterm birth (delivery before 37 weeks of gestation), low birth weight (<2500 g... [+18]